FGFR4 and cancer: As MDA-MB-453 and ZR-75.1 both contain the cancer-associated FGFR4-R388 (MDA-MB-453, homozygous; ZR-75.1, heterozygous), we further silenced FGFR4 in BT474 homozygous for FGFR4 G388, which increased MST1/N as well as full-length MST1/2 (Fig. 3g), indicating that both FGFR4 variants can suppress MST1.